Maxim Ratnikov Email & Phone Number

South San Francisco, California, United States

San Diego, California, United States

San Diego, California, United States

• Launched company’s first drug discovery project - selective kinase inhibitor for oncology indication• Created drug discovery infrastructure (wet and dry lab) and started discussions for a joint drug discovery partnership• Led development of an automatic synthesis platform capable of synthesizing of 100+ final compounds per week through up to 7-steps and without any limitations for synthetic methods• Consulted startup clients on screening technologies and lead series selection• Established and managed logistics with multiple suppliers and CROs• Proposed several projects in cardiovascular and metabolic diseases• Initiated and led development of computational tools in cheminformatics, ML in process improvement, retrosynthetic AI and docking• Led partnerships with two AI companies aimed at increasing efficiency of screening, docking and ADME predictions• Assembled and led a team with diverse skills – medicinal chemist, two operators, hardware engineer, software engineer, cheminformatician

San Diego, California, United States

• Led team of four medicinal chemists (2 PhD) and one computational chemist (1 PhD) towards the best-in-class candidate for a highly competitive oncology target• Led scaffold hop segment of a flagship project relying on docking and molecular dynamics simulations• Initiated investigation into new class of oncology targets• Progressed to decision points scaffolds in soft drug and covalent inhibitors for target-based oncology indications• Led exploration of properties and deployment in MedChem projects of 3D scaffolds

Greater San Diego Area

• Co-designed LXE408 (clinical candidate for Visceral Leishmaniasis)• Contributed to one clinical candidate in connective tissue regeneration• Progressed to decision points 5+ scaffolds for structure-based oncology projects and phenotypic regenerative medicine projects• Converted two phenotypic campaigns into structure-based drug design projects using pull-down probes and gene expression panels• Explored new therapeutic modalities - RNA binding small molecules and molecular tissue targeting• Led development of photochemical and photoredox methods (scale up, parallel synthesis, DNA-encoded libraries, target ID micromapping)• Led industry-academia collaborations

Greater San Diego Area

• Co-designed LXE408 (Phase II clinical candidate for Visceral Leishmaniasis)• Contributed to one clinical candidate in pulmonary regenerative medicine space• Explored complex natural products and 3D scaffolds• Converted one phenotypic campaign into structure-based drug design projects using resistance studies• Led development of photochemical and photoredox methods (scale up, fragment-based screening libraries, DNA-encoded libraries)• Trained and consulted medicinal chemist in new technologies• Established key specifications for lab-scale photo-flow hardware• Designed novel building blocks and chemical libraries• Developed late-stage functionalization protocols

Greater San Diego Area

• Contributed to design of Visceral Leishmaniasis, Cutaneous Leishmaniasis, Chagas and Human African Trypanosomiasis lead candidate• Developed of photochemical methods at global Novartis• Led development of flow chemistry• Led exploration of properties and deployment in MedChem projects of 3D scaffolds• Co-designed and coordinated hardware development for photochemistry

La Jolla, Ca

- improved ten-fold of activity of water surface as an electrophilic catalyst- employed sea water, an abundant renewable resource, in four organic transformations- applied boronic acid as sole catalysts in peptide bond formation from acid and amine- provided computational rationale to novel types of Cu-catalyzed azide-alkyne cycloadditions (CuAAC).

College Park, Md

- developed new catalytic oxidation methodologies- refined mechanisms of hydroperoxide-based phenol and aniline oxidations- developed ligand-free aniline C-H functionalization in presence of ferric chloride and molecular oxygen- synthesized a natural product (halleridone) and a variety of radical traps- selectively functionalized steroids (up to 10 g scale)

Lexington, Ky

- synthesized peptide libraries on a solid support (up to 2 g scale)- developed Stille coupling catalyzed by Pd nanoparticle-peptide complex- classified unknown waste chemicals

- proposed and validated model for structure-activity relationship of poly-nitrogen-containing heterocyclic fragment- synthesized and determined properties of novel heterocyclic compounds (supervisor Dr. Churakov, 2001-2006)- developed of Lewis acid-free electrophilic addition reactions (supervisor Dr. Smit, 2006-2007)

Doctor Of Philosophy (Phd), Organic Chemistry, 4.0

Master Of Science (Ms), Organic Chemistry, 3.6

Activities and Societies: Research at N.D. Zelinsky Institute of Organic Chemistry: - laboratory of nitro compounds [2001-2006].